PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
40.35%
Similar G&A growth to CRVO's 37.03%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
24.17%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
22.03%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
22.03%
Total costs growth 1.25-1.5x CRVO's 15.98%. Martin Whitman would scrutinize control.
-100.00%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
24.17%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-22.02%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9.98%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-22.30%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
9.98%
Tax expense change of 9.98% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-22.30%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.29%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.29%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.